DiGeorge Syndrome Diagnosis: A Comprehensive Guide for Healthcare Professionals

Introduction

DiGeorge Syndrome (DGS), also known as 22q11.2 deletion syndrome, is a congenital disorder stemming from a microdeletion on chromosome 22 at the 22q11.2 locus. This genetic anomaly disrupts the proper development of the pharyngeal pouches during embryogenesis. These pouches are crucial for forming various structures, including the middle and external ear, maxilla, mandible, palatine tonsils, thyroid, parathyroids, thymus, aortic arch, and cardiac outflow tract. Consequently, DGS manifests with a wide array of features, most notably cardiac anomalies, recurrent infections, distinctive facial features, thymic hypoplasia or aplasia, cleft palate, developmental delays, and hypocalcemia. Accurate and timely Digeorge Diagnosis is critical for effective management and improving patient outcomes.

First described in 1828, the syndrome was comprehensively characterized by Dr. Angelo DiGeorge in 1965, who highlighted the triad of immunodeficiency, hypoparathyroidism, and congenital heart disease. DGS falls under the broader category of 22q11 deletion syndromes, which historically included conditions like Shprintzen-Goldberg syndrome, velocardiofacial syndrome, and others. Despite sharing a similar genetic origin, the phenotypic variability led to different terminologies, causing diagnostic confusion and potential delays in DiGeorge diagnosis. Current medical consensus favors using these names interchangeably, acknowledging the spectrum of presentations within 22q11.2 deletion syndrome.

A hallmark of DGS is thymic hypoplasia or aplasia, impacting T lymphocyte development and leading to varying degrees of immunodeficiency. While complete thymic absence is rare, its association with severe combined immunodeficiency (SCID) underscores the importance of early DiGeorge diagnosis to manage immune deficits. Cardiac anomalies are prevalent, and other manifestations can include palatal, renal, ocular, and gastrointestinal issues. Skeletal defects, psychiatric disorders, and developmental delays are also significant concerns. Cognitive development in DGS can be complex, often presenting as cognitive decline rather than early-onset intellectual disability. Therefore, an individualized, thorough evaluation and interprofessional care approach are essential throughout the patient’s life following a DiGeorge diagnosis.

Etiology

The primary cause of DGS is a microdeletion in chromosome 22, specifically at the 22q11.2 locus. This deletion accounts for approximately 90% of DGS cases and typically occurs de novo, meaning it is not inherited from parents. Researchers have identified over 90 genes within this region, with the T-box transcription factor 1 (TBX1) being the most extensively studied. Studies using mouse models have shown that TBX1 plays a critical role in the development of the heart, thymus, and parathyroid glands. Furthermore, TBX1 is implicated in neuromicrovascular anomalies, potentially explaining the behavioral and developmental abnormalities observed in DGS. Understanding the etiology is fundamental for improving DiGeorge diagnosis and genetic counseling.

Epidemiology

Microdeletion of 22q11.2 is the most prevalent microdeletion syndrome, affecting about 0.1% of fetuses. The incidence in live births is estimated to be between 1 in 4000 and 6000. The discrepancy between fetal and live birth prevalence might be attributed to underreporting or the possibility that some 22q11.2 microdeletions result in embryonically lethal phenotypes, as suggested by animal studies.

The true prevalence of 22q11.2 microdeletion and, consequently, the need for accurate DiGeorge diagnosis may be underestimated for several reasons. First, not all individuals with the microdeletion exhibit pronounced craniofacial abnormalities, leading to missed diagnoses without genetic testing. For instance, African-American children may present with less typical craniofacial features of DGS. Second, access to genetic testing, crucial for confirming DiGeorge diagnosis, is not universally available. Therefore, more extensive population studies are necessary to fully understand the spectrum and prevalence of 22q11.2 microdeletions across diverse populations and improve diagnostic rates.

Pathophysiology

DGS pathophysiology is directly linked to the 22q11.2 microdeletion, which encompasses over 90 genes. This genetic loss results in a broad spectrum of phenotypes, with cardiac anomalies, hypocalcemia, and thymic hypoplasia being the most frequently observed.

At the genetic level, TBX1 dysfunction is strongly associated with the cardinal features of DGS. TBX1’s role in the embryologic development of pharyngeal pouches is crucial. Its deficiency leads to the maldevelopment or absence of the thymus and parathyroid glands. Animal models, such as TBX1 knockout mice and zebrafish, have been instrumental in elucidating the embryologic basis of DGS. Studies in mice lacking TBX1 have revealed severe defects in pharyngeal structures, the heart, thymus, and parathyroid glands, along with behavioral disturbances. Similarly, zebrafish models with TBX1 knockouts exhibit thymus and pharyngeal arch defects, as well as ear and thymus malformations. These findings underscore the importance of TBX1 in the pathogenesis of DGS and its relevance to DiGeorge diagnosis.

Furthermore, research on 22q11.2 knockout mouse models has revealed molecular and behavioral changes relevant to psychiatric conditions like Parkinson’s disease, autism spectrum disorder, attention deficit hyperactivity disorder, and schizophrenia. These insights, coupled with neuromicrovascular pathology in TBX1 knockout mice, suggest a molecular basis for the psychiatric comorbidities associated with DGS. Notably, individuals with DGS have a significantly increased risk (30-fold) of developing schizophrenia, highlighting the complex interplay between genetic deletion and broader health outcomes.

History and Physical

A detailed history and physical examination are paramount in the DiGeorge diagnosis process. Given the wide range of disease severity, clinical suspicion arising from history and physical findings is often the first step toward further evaluation. While most cases are diagnosed prenatally or in childhood, DiGeorge diagnosis can occur in adulthood as well.

Developmental delays, particularly in motor milestones like rolling over and sitting up, are often the first indicators noticed by parents. These delays can be accompanied by speech and learning difficulties. In older individuals, behavioral issues in the context of a history of developmental delays may be the primary presenting symptom prompting a DiGeorge diagnosis investigation.

Key historical points to consider include:

• Family history of confirmed or suspected DGS.
• Family members with abnormal genetic testing results.
• Delays in achieving developmental milestones.
• Behavioral disturbances.
• Cyanosis, exercise intolerance, or cardiac symptoms.
• Recurrent infections suggestive of T-cell deficiency.
• Speech difficulties.
• Feeding problems and/or failure to thrive.
• Muscle spasms, twitching, tetany, or seizures.

Physical examination findings suggestive of DGS can include:

• Cardiopulmonary Evaluation: Murmurs, cyanosis, clubbing, or edema may indicate aortic arch anomalies or conotruncal defects such as tetralogy of Fallot, truncus arteriosus, pulmonary atresia with ventricular septal defect, transposition of the great vessels, interrupted aortic arch, or tricuspid atresia.
• Craniofacial Examination: Characteristic facial features may include cleft palate, hypertelorism, ear anomalies, short down-slanting palpebral fissures, short philtrum, and hypoplasia of the maxilla or mandible.
• Signs of Immunodeficiency: Recurrent sinopulmonary infections due to T cell deficiency from thymic hypoplasia.
• Signs of Hypocalcemia: Twitching and muscle spasms due to parathyroid hypoplasia. Positive Chvostek’s and Trousseau’s signs may be elicited.
• Neurodevelopmental Assessment: Delayed development, unusual behavior, or signs of psychiatric disorders.

Facial features often associated with DiGeorge Syndrome, including elongated face, hooded eyelids, and small ears.

Evaluation

Definitive DiGeorge diagnosis relies on identifying the microdeletion of chromosome 22 at the 22q11.2 locus. Traditional cytogenetic techniques like Giemsa banding are insufficient for detecting microdeletions. Therefore, specialized genetic tests are necessary for accurate DiGeorge diagnosis. These include:

• Fluorescence In Situ Hybridization (FISH): A common and rapid method for detecting the 22q11.2 deletion.
• Multiplex Ligation-dependent Probe Amplification (MLPA): Another technique to identify deletions and duplications in specific genomic regions.
• Single Nucleotide Polymorphism (SNP) Array: Provides a genome-wide analysis and can detect microdeletions.
• Comparative Genomic Hybridization (CGH) Microarray: Detects chromosomal copy number variations, including microdeletions.
• Quantitative Polymerase Chain Reaction (qPCR): Can quantify specific DNA sequences and detect deletions.

The availability and cost of these advanced genetic tests can sometimes delay DiGeorge diagnosis, particularly in resource-limited settings.

Once DGS is suspected or diagnosed, comprehensive evaluations are crucial, especially if life-threatening cardiac or immunologic deficits are present. Recommended evaluations include:

• Echocardiogram: To assess for conotruncal and other cardiac abnormalities.
• Complete Blood Count with Differential: To evaluate overall blood cell counts and identify potential infections.
• T and B Lymphocyte Subset Panels: To assess the extent of immunodeficiency.
• Flow Cytometry: To analyze T cell repertoire and function.
• Immunoglobulin Levels: To measure antibody levels (IgG, IgA, IgM).
• Vaccine Titers: To evaluate immune response to vaccines.
• Serum Ionized Calcium and Phosphorus Levels: To assess for hypocalcemia and hyperphosphatemia.
• Parathyroid Hormone Level: To evaluate parathyroid function.
• Chest X-ray: To assess thymic shadow and size.
• Renal Ultrasound: To screen for renal and genitourinary anomalies.
• Serum Creatinine: To evaluate renal function.
• Thyroid Stimulating Hormone (TSH): To screen for thyroid dysfunction.
• Growth Hormone Deficiency Testing: To evaluate growth issues.

The variability in disease severity makes DiGeorge diagnosis and evaluation complex. Cases with significant cardiac, thymic, and craniofacial features are more readily recognized than milder presentations. Advancements in genomic studies and facial recognition technology hold promise for improving the efficiency and accuracy of DiGeorge diagnosis in the future.

Karyotype showing a deletion in chromosome 22, characteristic of DiGeorge Syndrome.

Treatment / Management

Management of DGS necessitates a multidisciplinary, interprofessional care approach. Following DiGeorge diagnosis, a tailored treatment plan is essential to address the diverse manifestations of the syndrome.

• Immunodeficiency Management: Many DGS patients have mild immunodeficiency with preserved T cell function. Regular follow-up with an immunologist is recommended. Neonates with complete DGS (cDGS) require stringent management, including isolation, intravenous immunoglobulin (IVIG), prophylactic antibiotics, and potentially thymic or hematopoietic stem cell transplant (HSCT). Immunization schedules, booster doses, IVIG, and antibiotic prophylaxis should be individualized based on laboratory findings and immune status. Antibody titers post-vaccination should be monitored every 6-12 months to guide revaccination needs. The use of live vaccines (MMR, oral polio, rotavirus) is debated. Current evidence suggests they are generally safe and effective in children over one year with proven vaccine response and adequate CD4 and CD8 counts. However, rotavirus vaccination has been linked to diarrheal illness in SCID patients and should be avoided in infants with reduced T cell counts.
• Cardiac Anomaly Management: Cardiac anomalies, if not detected prenatally, may present as life-threatening cyanotic heart disease shortly after birth. Urgent pediatric cardiothoracic surgery consultation may be necessary. Blood products for transfusion should be irradiated, CMV-negative, and leukocyte-reduced to prevent transfusion-associated graft-versus-host disease and minimize lung injury, especially in surgical cases requiring cardiopulmonary bypass.
• Cleft Palate Repair: Cleft palate requires evaluation by otolaryngologists, plastic surgeons, or oral & maxillofacial surgeons experienced in cleft palate repair. Surgical correction improves feeding, speech, and reduces sinopulmonary infections.
• Hypocalcemia Management: Hypocalcemia is typically managed with calcium and vitamin D supplementation. Recombinant human PTH is an option for patients unresponsive to standard therapy.
• Autoimmune Disease Monitoring: Autoimmune diseases (ITP, rheumatoid arthritis, autoimmune hemolytic anemia, Graves’ disease, Hashimoto’s thyroiditis) are common in DGS. Regular monitoring for autoimmune symptoms is crucial.
• Audiologic Evaluation: Hearing assessments are necessary, especially in children with developmental delays or suspected hearing difficulties.
• Early Intervention Services: Early intervention programs are beneficial for children with cognitive and behavioral developmental delays.
• Speech Therapy: Speech therapy addresses language difficulties related to craniofacial anomalies and/or cognitive impairment.
• Psychiatric Care: Psychiatric care is essential for managing depressive and psychotic symptoms, given the increased risk of schizophrenia and other psychiatric disorders in DGS.
• Genetic Counseling: Genetic counseling is recommended for parents of a child with DGS considering future pregnancies, and for individuals with DGS planning to have children. Recurrence risk is 50% if a parent carries the 22q11.2 deletion.

Advanced Approaches for Complete DiGeorge Anomaly:

Complete DGS (cDGS) with absent thymus function and impaired T cell development is often fatal by age 2 due to severe infections. T cell-replete HSCT is a proposed treatment, but it only engrafts post-thymic T cells due to thymic absence. HSCT survival rates vary (33% with matched unrelated donors, 60% with matched sibling transplants). Thymus transplantation is now an FDA-approved standard care, aiming to generate naive T cells with a broad T-cell receptor repertoire. Thymus tissue is typically transplanted into the quadriceps under general anesthesia. Studies show up to 75% long-term survival with thymus transplantation, but autoimmune sequelae (hemolysis, thyroiditis, thrombocytopenia, enteropathy, neutropenia) are common.

Differential Diagnosis

Many features of DGS can occur as isolated anomalies in individuals without DGS, making DiGeorge diagnosis sometimes challenging.

Conditions with overlapping features include:

• Smith-Lemli-Opitz Syndrome: Shares features like polydactyly and cleft palate.
• Oculo-Auriculo Vertebral (Goldenhar) Syndrome (OAVS): Presents with ear anomalies, heart disease, vertebral defects, and renal anomalies. Often sporadic.
• Alagille Syndrome: Shares butterfly vertebrae, congenital heart disease, and posterior embryotoxon.
• VATER Association: Overlaps with heart disease, vertebral, renal, and limb anomalies. VATER is a diagnosis of exclusion with unknown etiology.
• CHARGE Syndrome: Has significant overlap in congenital heart disease, palatal issues, choanal atresia, coloboma, renal, growth deficiency, ear anomalies/hearing loss, facial palsy, developmental differences, genitourinary anomalies, and immunodeficiency.

Genetic consultation and a comprehensive clinical picture are essential for accurate DiGeorge diagnosis and differentiation from these overlapping syndromes.

Prognosis

Prognosis in DGS varies widely based on disease severity. Less than 1% of patients have complete DGS, the most severe form with a very poor prognosis. Without thymic or HSCT, these infants usually die within the first year of life. Even with transplantation, prognosis remains guarded. Studies show survival to two years in only about 36 out of 50 infants who received thymus transplants for complete DGS.

Patients with partial DGS have a more variable prognosis, dependent on the severity of associated pathologies. While some may not survive infancy due to severe cardiac issues, many live into adulthood. DGS is likely underdiagnosed, and many undiagnosed adults with milder forms thrive with subtle or undetected congenital anomalies and minor intellectual or social impairments. Improved genetic diagnostics are expected to enhance understanding of DGS and refine prognosis in the future.

Complications

Cardiac and craniofacial anomalies associated with DGS often require surgical intervention. As with any surgery, risks of bleeding, infection, and prolonged hospitalization exist. These risks are amplified in immunocompromised DGS patients.

Long-term follow-up is crucial to monitor for potential complications, including severe recurrent infections, autoimmune diseases, and hematologic malignancies.

Deterrence and Patient Education

Patient education for parents of children with DGS is vital and should be tailored to the child’s specific condition severity. Discussion points should include:

• Early signs and symptoms of infection.
• Signs of hypocalcemia.
• Safe medication use.
• Surgical options.
• Immunotherapy options.
• Genetic counseling.
• Speech therapy benefits for feeding or language issues.
• Developmental milestones and signs of delay.
• Benefits of early intervention programs.
• Signs and symptoms of psychiatric disorders.

Pearls and Other Issues

DiGeorge syndrome is easily recalled with the “CATCH-22” mnemonic, aiding in DiGeorge diagnosis suspicion:

Conotruncal cardiac anomalies
Abnormal facies
Thymic hypoplasia
Cleft palate
Hypocalcemia
22q11.2 microdeletion

Enhancing Healthcare Team Outcomes

Effective management of DGS requires a collaborative, interprofessional team. Obstetricians and genetic counselors play a role in prenatal DiGeorge diagnosis and management. Postnatally, neonatologists, primary care physicians, immunologists, cardiothoracic surgeons, craniofacial surgeons, and other specialists are involved. Nurses, pharmacists, psychologists, speech therapists, and other healthcare professionals are essential team members. Pharmacists ensure appropriate medication selection and dosing. Nurses provide parent education and monitor treatment progress. Psychologists address developmental and family support needs. Lifelong, consistent follow-up with all involved specialists is crucial. Open communication and collaboration are paramount for optimal patient outcomes following DiGeorge diagnosis.

Diagnosis and management are complex, and an interprofessional approach is key to reducing morbidity and mortality associated with DGS. Current evidence for DGS management is level 5, emphasizing the need for individualized, patient-centered treatment strategies.

Review Questions

(Note: Review questions are present in the original article, but per instructions, they are not to be included in the rewritten article.)

References

(References are identical to the original article and are listed below for completeness.)

1.McDonald-McGinn DM, Sullivan KE, Marino B, Philip N, Swillen A, Vorstman JA, Zackai EH, Emanuel BS, Vermeesch JR, Morrow BE, Scambler PJ, Bassett AS. 22q11.2 deletion syndrome. Nat Rev Dis Primers. 2015 Nov 19;1:15071. [PMC free article: PMC4900471] [PubMed: 27189754]

2.Fomin AB, Pastorino AC, Kim CA, Pereira CA, Carneiro-Sampaio M, Abe-Jacob CM. DiGeorge Syndrome: a not so rare disease. Clinics (Sao Paulo). 2010;65(9):865-9. [PMC free article: PMC2954737] [PubMed: 21049214]

3.Cascella M, Muzio MR. Early onset intellectual disability in chromosome 22q11.2 deletion syndrome. Rev Chil Pediatr. 2015 Jul-Aug;86(4):283-6. [PubMed: 26358864]

4.Cioffi S, Martucciello S, Fulcoli FG, Bilio M, Ferrentino R, Nusco E, Illingworth E. Tbx1 regulates brain vascularization. Hum Mol Genet. 2014 Jan 01;23(1):78-89. [PubMed: 23945394]

5.Paylor R, Glaser B, Mupo A, Ataliotis P, Spencer C, Sobotka A, Sparks C, Choi CH, Oghalai J, Curran S, Murphy KC, Monks S, Williams N, O’Donovan MC, Owen MJ, Scambler PJ, Lindsay E. Tbx1 haploinsufficiency is linked to behavioral disorders in mice and humans: implications for 22q11 deletion syndrome. Proc Natl Acad Sci U S A. 2006 May 16;103(20):7729-34. [PMC free article: PMC1472513] [PubMed: 16684884]

6.Grati FR, Molina Gomes D, Ferreira JC, Dupont C, Alesi V, Gouas L, Horelli-Kuitunen N, Choy KW, García-Herrero S, de la Vega AG, Piotrowski K, Genesio R, Queipo G, Malvestiti B, Hervé B, Benzacken B, Novelli A, Vago P, Piippo K, Leung TY, Maggi F, Quibel T, Tabet AC, Simoni G, Vialard F. Prevalence of recurrent pathogenic microdeletions and microduplications in over 9500 pregnancies. Prenat Diagn. 2015 Aug;35(8):801-9. [PubMed: 25962607]

7.Botto LD, May K, Fernhoff PM, Correa A, Coleman K, Rasmussen SA, Merritt RK, O’Leary LA, Wong LY, Elixson EM, Mahle WT, Campbell RM. A population-based study of the 22q11.2 deletion: phenotype, incidence, and contribution to major birth defects in the population. Pediatrics. 2003 Jul;112(1 Pt 1):101-7. [PubMed: 12837874]

8.McDonald-McGinn DM, Minugh-Purvis N, Kirschner RE, Jawad A, Tonnesen MK, Catanzaro JR, Goldmuntz E, Driscoll D, Larossa D, Emanuel BS, Zackai EH. The 22q11.2 deletion in African-American patients: an underdiagnosed population? Am J Med Genet A. 2005 Apr 30;134(3):242-6. [PMC free article: PMC2810968] [PubMed: 15754359]

9.Zhang Z, Huynh T, Baldini A. Mesodermal expression of Tbx1 is necessary and sufficient for pharyngeal arch and cardiac outflow tract development. Development. 2006 Sep;133(18):3587-95. [PMC free article: PMC1850622] [PubMed: 16914493]

10.Guner-Ataman B, González-Rosa JM, Shah HN, Butty VL, Jeffrey S, Abrial M, Boyer LA, Burns CG, Burns CE. Failed Progenitor Specification Underlies the Cardiopharyngeal Phenotypes in a Zebrafish Model of 22q11.2 Deletion Syndrome. Cell Rep. 2018 Jul 31;24(5):1342-1354.e5. [PMC free article: PMC6261257] [PubMed: 30067987]

11.Sumitomo A, Horike K, Hirai K, Butcher N, Boot E, Sakurai T, Nucifora FC, Bassett AS, Sawa A, Tomoda T. A mouse model of 22q11.2 deletions: Molecular and behavioral signatures of Parkinson’s disease and schizophrenia. Sci Adv. 2018 Aug;4(8):eaar6637. [PMC free article: PMC6093626] [PubMed: 30116778]

12.Meechan DW, Maynard TM, Tucker ES, Fernandez A, Karpinski BA, Rothblat LA, LaMantia AS. Modeling a model: Mouse genetics, 22q11.2 Deletion Syndrome, and disorders of cortical circuit development. Prog Neurobiol. 2015 Jul;130:1-28. [PMC free article: PMC5019355] [PubMed: 25866365]

13.McDonald-McGinn DM, Sullivan KE. Chromosome 22q11.2 deletion syndrome (DiGeorge syndrome/velocardiofacial syndrome). Medicine (Baltimore). 2011 Jan;90(1):1-18. [PubMed: 21200182]

14.Kruszka P, Addissie YA, McGinn DE, Porras AR, Biggs E, Share M, Crowley TB, Chung BH, Mok GT, Mak CC, Muthukumarasamy P, Thong MK, Sirisena ND, Dissanayake VH, Paththinige CS, Prabodha LB, Mishra R, Shotelersuk V, Ekure EN, Sokunbi OJ, Kalu N, Ferreira CR, Duncan JM, Patil SJ, Jones KL, Kaplan JD, Abdul-Rahman OA, Uwineza A, Mutesa L, Moresco A, Obregon MG, Richieri-Costa A, Gil-da-Silva-Lopes VL, Adeyemo AA, Summar M, Zackai EH, McDonald-McGinn DM, Linguraru MG, Muenke M. 22q11.2 deletion syndrome in diverse populations. Am J Med Genet A. 2017 Apr;173(4):879-888. [PMC free article: PMC5363275] [PubMed: 28328118]

15.Al-Sukaiti N, Reid B, Lavi S, Al-Zaharani D, Atkinson A, Roifman CM, Grunebaum E. Safety and efficacy of measles, mumps, and rubella vaccine in patients with DiGeorge syndrome. J Allergy Clin Immunol. 2010 Oct;126(4):868-9. [PubMed: 20810153]

16.Bakare N, Menschik D, Tiernan R, Hua W, Martin D. Severe combined immunodeficiency (SCID) and rotavirus vaccination: reports to the Vaccine Adverse Events Reporting System (VAERS). Vaccine. 2010 Sep 14;28(40):6609-12. [PubMed: 20674876]

17.McGhee SA, Lloret MG, Stiehm ER. Immunologic reconstitution in 22q deletion (DiGeorge) syndrome. Immunol Res. 2009;45(1):37-45. [PubMed: 19238335]

18.Janda A, Sedlacek P, Hönig M, Friedrich W, Champagne M, Matsumoto T, Fischer A, Neven B, Contet A, Bensoussan D, Bordigoni P, Loeb D, Savage W, Jabado N, Bonilla FA, Slatter MA, Davies EG, Gennery AR. Multicenter survey on the outcome of transplantation of hematopoietic cells in patients with the complete form of DiGeorge anomaly. Blood. 2010 Sep 30;116(13):2229-36. [PMC free article: PMC4425440] [PubMed: 20530285]

19.Davies EG, Cheung M, Gilmour K, Maimaris J, Curry J, Furmanski A, Sebire N, Halliday N, Mengrelis K, Adams S, Bernatoniene J, Bremner R, Browning M, Devlin B, Erichsen HC, Gaspar HB, Hutchison L, Ip W, Ifversen M, Leahy TR, McCarthy E, Moshous D, Neuling K, Pac M, Papadopol A, Parsley KL, Poliani L, Ricciardelli I, Sansom DM, Voor T, Worth A, Crompton T, Markert ML, Thrasher AJ. Thymus transplantation for complete DiGeorge syndrome: European experience. J Allergy Clin Immunol. 2017 Dec;140(6):1660-1670.e16. [PMC free article: PMC5716670] [PubMed: 28400115]

20.Markert ML, Devlin BH, Chinn IK, McCarthy EA. Thymus transplantation in complete DiGeorge anomaly. Immunol Res. 2009;44(1-3):61-70. [PMC free article: PMC4951183] [PubMed: 19066739]